These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 23535062)

  • 1. Impact of isolated germline JAK2V617I mutation on human hematopoiesis.
    Mead AJ; Chowdhury O; Pecquet C; Dusa A; Woll P; Atkinson D; Burns A; Score J; Rugless M; Clifford R; Moule S; Bienz N; Vyas P; Cross N; Gale RE; Henderson S; Constantinescu SN; Schuh A; Jacobsen SE
    Blood; 2013 May; 121(20):4156-65. PubMed ID: 23535062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).
    Dunbar A; Nazir A; Levine R
    Curr Protoc Pharmacol; 2017 Jun; 77():14.40.1-14.40.19. PubMed ID: 28640953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deletion of Stat3 in hematopoietic cells enhances thrombocytosis and shortens survival in a JAK2-V617F mouse model of MPN.
    Grisouard J; Shimizu T; Duek A; Kubovcakova L; Hao-Shen H; Dirnhofer S; Skoda RC
    Blood; 2015 Mar; 125(13):2131-40. PubMed ID: 25595737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F.
    Lundberg P; Takizawa H; Kubovcakova L; Guo G; Hao-Shen H; Dirnhofer S; Orkin SH; Manz MG; Skoda RC
    J Exp Med; 2014 Oct; 211(11):2213-30. PubMed ID: 25288396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm.
    Sangkhae V; Etheridge SL; Kaushansky K; Hitchcock IS
    Blood; 2014 Dec; 124(26):3956-63. PubMed ID: 25339357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
    Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
    PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of germline JAK2 activation mutation JAK2 V625F in the pathology of myeloproliferative neoplasms.
    Wu QY; Ma MM; Fu L; Zhu YY; Liu Y; Cao J; Zhou P; Li ZY; Zeng LY; Li F; Wang XY; Xu KL
    Int J Biol Macromol; 2018 Sep; 116():1064-1073. PubMed ID: 29782975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms.
    Hinds DA; Barnholt KE; Mesa RA; Kiefer AK; Do CB; Eriksson N; Mountain JL; Francke U; Tung JY; Nguyen HM; Zhang H; Gojenola L; Zehnder JL; Gotlib J
    Blood; 2016 Aug; 128(8):1121-8. PubMed ID: 27365426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?
    Chen E; Mullally A
    Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):268-76. PubMed ID: 25696866
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow.
    Kirabo A; Park SO; Majumder A; Gali M; Reinhard MK; Wamsley HL; Zhao ZJ; Cogle CR; Bisht KS; Keserü GM; Sayeski PP
    Neoplasia; 2011 Nov; 13(11):1058-68. PubMed ID: 22131881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel activating, germline JAK2 mutation, JAK2R564Q, causes familial essential thrombocytosis.
    Etheridge SL; Cosgrove ME; Sangkhae V; Corbo LM; Roh ME; Seeliger MA; Chan EL; Hitchcock IS
    Blood; 2014 Feb; 123(7):1059-68. PubMed ID: 24381227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The JAK2V617F mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases?
    James C
    Hematology Am Soc Hematol Educ Program; 2008; ():69-75. PubMed ID: 19074061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The regulation of normal and neoplastic hematopoiesis is dependent on microenvironmental cells.
    Kaushansky K; Zhan H
    Adv Biol Regul; 2018 Aug; 69():11-15. PubMed ID: 29970351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK2(V617I) results in cytokine hypersensitivity without causing an overt myeloproliferative disorder in a mouse transduction-transplantation model.
    Brooks SA; Luty SB; Lai HY; Morse SJ; Nguyen TK; Royer LR; Agarwal A; Druker BJ; Fleischman AG
    Exp Hematol; 2016 Jan; 44(1):24-9.e1. PubMed ID: 26458983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased basal intracellular signaling patterns do not correlate with JAK2 genotype in human myeloproliferative neoplasms.
    Anand S; Stedham F; Gudgin E; Campbell P; Beer P; Green AR; Huntly BJ
    Blood; 2011 Aug; 118(6):1610-21. PubMed ID: 21653937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of mutations in myeloproliferative neoplasms.
    Levine RL
    Best Pract Res Clin Haematol; 2009 Dec; 22(4):489-94. PubMed ID: 19959098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JAK2 mutations and clinical practice in myeloproliferative neoplasms.
    Tefferi A
    Cancer J; 2007; 13(6):366-71. PubMed ID: 18032973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell autonomous expression of CXCL-10 in JAK2V617F-mutated MPN.
    Schnöder TM; Eberhardt J; Koehler M; Bierhoff HB; Weinert S; Pandey AD; Nimmagadda SC; Wolleschak D; Jöhrens K; Fischer T; Heidel FH
    J Cancer Res Clin Oncol; 2017 May; 143(5):807-820. PubMed ID: 28233092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα.
    Hasan S; Lacout C; Marty C; Cuingnet M; Solary E; Vainchenker W; Villeval JL
    Blood; 2013 Aug; 122(8):1464-77. PubMed ID: 23863895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.
    Mullally A; Bruedigam C; Poveromo L; Heidel FH; Purdon A; Vu T; Austin R; Heckl D; Breyfogle LJ; Kuhn CP; Kalaitzidis D; Armstrong SA; Williams DA; Hill GR; Ebert BL; Lane SW
    Blood; 2013 May; 121(18):3692-702. PubMed ID: 23487027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.